Šalis: Jungtinės Valstijos
kalba: anglų
Šaltinis: NLM (National Library of Medicine)
MESALAMINE (UNII: 4Q81I59GXC) (MESALAMINE - UNII:4Q81I59GXC)
Zydus Pharmaceuticals USA Inc.
MESALAMINE
MESALAMINE 1.2 g
ORAL
PRESCRIPTION DRUG
Mesalamine delayed-release tablets are indicated for the: - induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. - treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg. Mesalamine delayed-release tablets are contraindicated in patients with known or suspected hypersensitivity to salicylates, aminosalicylates, or to any of the ingredients of mesalamine delayed-release tablets [see Warnings and Precautions (5.3), Adverse Reactions (6.2), Description (11) ]. Risk Summary Published data from meta-analyses, cohort studies, and case series on the use of mesalamine during pregnancy have not reliably informed an association with mesalamine and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). There are adverse effects on maternal and fetal outcomes associated with ulcerative colitis in pregnancy (see Clinical Considerations). In animal reproduction studies, there were no adv
Mesalamine Delayed-Release Tablets USP, 1.2 g are pale red-brown, oval-shaped, biconvex, bevel film-coated tablets debossed with the '711' on one side and plain on other side and are supplied as follows: NDC 68382-711-64 in bottle of 34 tablets with child-resistant closure NDC 68382-711-19 in bottle of 120 tablets with child-resistant closure Storage Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container.
Abbreviated New Drug Application
Zydus Pharmaceuticals USA Inc. ---------- Manufactured by: Zydus Lifesciences Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ 08534 Rev.: 10/23 Revised: 10/2023 Document Id: d9ce9589-6aee-4dc3-a71b-f1c32ab9f552 34391-3 Set id: 533bfaf5-0add-4b49-a4f2-ddea2b83f65d Version: 15 Effective Time: 20231026 Zydus Pharmaceuticals USA Inc. Perskaitykite visą dokumentą
MESALAMINE- MESALAMINE TABLET, DELAYED RELEASE ZYDUS PHARMACEUTICALS USA INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE MESALAMINE DELAYED- RELEASE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR MESALAMINE DELAYED-RELEASE TABLETS. MESALAMINE DELAYED-RELEASE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1987 RECENT MAJOR CHANGES Warnings and Precautions, Renal Impairment (5.1) 11/2022 INDICATIONS AND USAGE Mesalamine delayed-release tablets are an aminosalicylate indicated for the: induction and maintenance of remission in adult patients with mildly to moderately active ulcerative colitis. (1) treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg. (1) DOSAGE AND ADMINISTRATION ADMINISTRATION INSTRUCTIONS Evaluate renal function prior to initiation of mesalamine and periodically while on therapy. (2, 5.1) Swallow mesalamine delayed-release tablets whole; do not split or crush. (2) Administer mesalamine delayed-release tablets with food. (2) Drink an adequate amount of fluids. (2, 5.8) RECOMMENDED DOSAGE IN ADULTS _For induction of remission:_ 2.4 g to 4.8 g (two to four 1.2 g tablets) once daily. (2) _For maintenance of remission:_ 2.4 g (two 1.2 g tablets) once daily. (2) RECOMMENDED DOSAGE IN PEDIATRIC PATIENTS The recommended dosage for treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg who can swallow tablets whole is shown below: (2) Weight of Pediatric PatientOnce Daily Mesalamine Delayed Release Tablet Dosage Week 0 to Week 8 Week 0 to Week 8 24 kg to 35 kg 2.4 g (two 1.2- g tablets) 1.2 g (one 1.2-g tablet) Greater than 35 kg to 50 kg 3.6 g (three 1.2-g tablets) 2.4 g (two 1.2-g tablets) Greater than 50 kg 4.8 g (four 1.2- g tablets) 2.4 g (two 1.2-g tablets) DOSAGE FORMS AND STRENGTHS Delayed-Release Tablets: 1.2 g (3) CONTRAINDICATIONS Known or suspected hypersensitivity to salicylates or aminosalicylates or Perskaitykite visą dokumentą